Edition:
India

Novo Nordisk: Tresiba Shows Lower Risk Of Hypoglycaemia And Lower HbA1c Compared To Insulin Glargine U300 In People With Type 2 Diabetes


Thursday, 19 Sep 2019 

Sept 19 (Reuters) - Novo Nordisk A/S ::TRESIBA® SHOWED AN OVERALL LOWER RISK OF HYPOGLYCAEMIA AND SIGNIFICANTLY LOWER HBA1C WHEN COMPARED TO INSULIN GLARGINE U300 IN PEOPLE WITH TYPE 2 DIABETES.PRIMARY ENDPOINT, RATE OF OVERALL SYMPTOMATIC HYPOGLYCAEMIA IN MAINTENANCE PERIOD OF 36 WEEKS WHICH WAS TESTED FOR SUPERIORITY, WAS NUMERICALLY LOWER BUT NOT STATISTICALLY SIGNIFICANT VERSUS INSULIN GLARGINE U300.IN THIS HEAD-TO-HEAD TRIAL, TRESIBA® SIGNIFICANTLY REDUCED RATE OF SEVERE HYPOGLYCAEMIA BY 80% AND NOCTURNAL SYMPTOMATIC HYPOGLYCAEMIA BY 37% WHEN COMPARED WITH INSULIN GLARGINE U300 DURING MAINTENANCE PERIOD, AND BY 62% AND 43% RESPECTIVELY IN TOTAL TREATMENT PERIOD WHEN COMPARED WITH INSULIN GLARGINE U300.RATE OF OVERALL SYMPTOMATIC HYPOGLYCAEMIA WAS STATISTICALLY SIGNIFICANTLY LOWER IN FAVOUR OF TRESIBA® DURING TOTAL TREATMENT PERIOD OF UP TO 88 WEEKS.